DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Fizazi K, Tran N, Fein L. et al.
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Lancet Oncol 2019;
20: 686-700
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.